Generic Drug Development in Emerging Markets: The IP, Regulatory, and Commercial Playbook
Section 1: What ‘Pharmerging’ Actually Means in 2025 Defining the Tier Structure IQVIA’s ‘pharmerging’ classification groups approximately 21 countries by […]
Section 1: What ‘Pharmerging’ Actually Means in 2025 Defining the Tier Structure IQVIA’s ‘pharmerging’ classification groups approximately 21 countries by […]
Generics account for over 90% of all U.S. prescriptions filled while consuming roughly 18% of total prescription drug spending. That
A data-driven deep dive into Hatch-Waxman mechanics, ANDA strategy, Paragraph IV litigation economics, patent IP valuation, complex generics science, and
1. Why Drug Patent Portfolio Management Determines Who Wins — and Who Exits {#1} Pharmaceutical R&D is one of the
Executive Summary Biologics account for roughly 2% of U.S. prescriptions but consumed 38-40% of total pharmaceutical spending in 2023. In
Biosimilars and Out-of-Pocket Costs: The Complete Strategic Guide Read Post »
Why Pharmaceutical Patent Searching Is a Different Discipline Drug patent analysis sits at the intersection of medicinal chemistry, patent law,
Google Patents Fails Drug Patent Searches: The Definitive Guide for Pharma IP Teams Read Post »
Part 1: The True Price of Innovation — The Multi-Layered Cost of a Drug Patent Beyond the Filing Fee: The
Executive Summary The patent is the fundamental unit of value in the pharmaceutical industry. A single compound patent on a
The Future of Patent Intelligence Tools: How AI is Revolutionizing the Landscape Read Post »
Part I: Why This Matters — The Stakes of Drug Patent Intelligence The Numbers Behind a Bad Search The Tufts
Google Patents Fails Drug Patent Searches: The Complete IP Intelligence Guide for Pharma Read Post »
Get fresh news and insights, drug patent expirations & more…